Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Screening for spina bifida cystica. A cost-benefit analysis.

Literature DB >> 59616

Screening for spina bifida cystica. A cost-benefit analysis.

Abstract

The costs and economic benefits are examined of introducing a programme for the mass-screening of pregnancies for the detection and abortion of fetuses with spina bifida cystica. A benefit-cost index is derived, and the possible effects on it of making different input assumptions are discussed. It is considered that, on economic grounds, screening may be worthwhile only in populations in which the incidence of spina bifida is high.

Entities: Disease

Mesh：

Substances：
alpha-Fetoproteins

Year: 1976 PMID： 59616 PMCID： PMC478937 DOI： 10.1136/jech.30.1.40

Source DB: PubMed Journal: Br J Prev Soc Med ISSN： 0007-1242

24 in total

1. Congenital malformations of the central nervous system in Scotland.

Authors: J H EDWARDS
Journal: Br J Prev Soc Med Date: 1958-07

2. The technique, results and risks of amniocentesis for genetic reasons.

Authors: F K Bartsch; J Lundberg; J Wahlström
Journal: J Obstet Gynaecol Br Commonw Date: 1974-12

3. The fetus at risk.

Authors: T Chard
Journal: Lancet Date: 1974-10-12 Impact factor: 79.321

4. Prenatal diagnosis of spina bifida and anencephaly through maternal plasma-alpha-fetoprotein measurement.

Authors: D J Brock; A E Bolton; J B Scrimgeour
Journal: Lancet Date: 1974-04-27 Impact factor: 79.321

5. Prenatal diagnosis of spina bifida and anencephaly by maternal serum-alpha-fetoprotein measurement. A controlled study.

Authors: N J Wald; D J Brock; J Bonnar
Journal: Lancet Date: 1974-04-27 Impact factor: 79.321

5. Maternal serum alpha-fetoprotein screening for neural tube defects. Report of a combined study in Germany and short overview on screening in populations with low birth prevalence of neural tube defects.

Authors: W Fuhrmann; H K Weitzel
Journal: Hum Genet Date: 1985 Impact factor: 4.132

Screening for spina bifida cystica. A cost-benefit analysis.

1. Congenital malformations of the central nervous system in Scotland.

2. The technique, results and risks of amniocentesis for genetic reasons.

3. The fetus at risk.

4. Prenatal diagnosis of spina bifida and anencephaly through maternal plasma-alpha-fetoprotein measurement.

5. Prenatal diagnosis of spina bifida and anencephaly by maternal serum-alpha-fetoprotein measurement. A controlled study.

6. Amniotic-fluid alpha-fetoprotein in the antenatal diagnosis of spina bifida.

7. Implications of the treatment of myelomeningocele for the child and his family.

8. Myelocele and alpha-fetoprotein in amniotic fluid.

9. Raised alpha-fetoprotein in maternal serum with anencephalic pregnancy.

10. Results of selective early operation in myelomeningocele.

1. Economic approaches to alternative patterns of health care.

2. The periodic health examination. Canadian Task Force on the Periodic Health Examination.

3. Genetics and the quality of life.

4. When does mass screening for open neural tube defects in low-risk pregnancies result in cost savings?

5. Maternal serum alpha-fetoprotein screening for neural tube defects. Report of a combined study in Germany and short overview on screening in populations with low birth prevalence of neural tube defects.

6. How to read clinical journals: VII. To understand an economic evaluation (part A).

7. Measuring the benefits of screening for open neural tube defects.

8. Essentials of health economics. Part V--Assessing the costs and benefits of treatment alternatives.

9. Hazards of prenatal detection of neural-tube defects by screening maternal serum for alpha-fetoprotein.

10. Which prescriptive screening programmes are worth while?